Merck's Keytruda has received FDA approval for its use in combination with chemotherapy as a treatment for rare lung disease MPM, and also expanded for mesothelioma. The company announced these approvals on September 18th.
The drug is expected to drive growth for Merck, which boasts more than six blockbuster drugs in its portfolio. However, the stock has declined around 10.3% in the past three months due to a late-stage trial of combination treatment for colon cancer failing to meet main goal. Analysts have conflicting sentiments on whether this affects their buy or sell recommendations.
Merck's Keytruda is also being used as a second-line therapy and has shown promise in patients with EGFR-mutated non-small cell lung cancer (NSCLC). The company continues to solidify its position in the market, but some analysts have expressed cautious optimism about Merck's tulisokibart amid competitive markets.
The pharmaceutical giant is expected to benefit from a growing pipeline and steady future dividends. Keytruda has been Merck's top-selling medicine and biggest growth driver, making it an essential asset for the company's success in cancer treatment.
* AI generated summary of articles
MRK News
15-Oct-2024 4:00 AM CST - Yahoo Finance Exelixis, MRK Collaborate for Combination Studies on HNSCC and RCC EXEL is set to evaluate investigational zanzalintinib in combination with Merck;s Keytruda (pembrolizumab) and Welireg in head and neck cancer and renal cell carcinoma, respectively.
11-Oct-2024 8:00 AM CST - Zacks Merck & Co., Inc. (MRK) Is a Trending Stock: Facts to Know Before Betting on It Merck (MRK) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over the past month,
8-Oct-2024 6:35 AM CST - Seeking Alpha Merck posts late-stage trial win for Keytruda in head and neck cancer Merck (NYSE:MRK) announced Tuesday that its Phase 3 KEYNOTE-689, designed to evaluate its anti-PD-1 therapy Keytruda as a perioperative regimen in certain patients with head and neck cancer, reached the primary goal. Citing the results of the first interim ...
6-Oct-2024 9:15 PM CST - Business Insider Barclays Remains a Buy on Merck & Company (MRK) In a report released on October 4, Carter Gould from Barclays maintained a Buy rating on Merck & Company (MRK - Research Report),
Latest MRK Trades by Congress Members
24-SEP-2024 - Jonathan Jackson, IL (District 1) sold between $15,001 and $50,000.
Merck's Keytruda has received FDA approval for its use in combination with chemotherapy as a treatment for rare lung disease MPM, and also expanded for mesothelioma. The company announced these approvals on September 18th.
The drug is expected to drive growth for Merck, which boasts more than six blockbuster drugs in its portfolio. However, the stock has declined around 10.3% in the past three months due to a late-stage trial of combination treatment for colon cancer failing to meet main goal. Analysts have conflicting sentiments on whether this affects their buy or sell recommendations.
Merck's Keytruda is also being used as a second-line therapy and has shown promise in patients with EGFR-mutated non-small cell lung cancer (NSCLC). The company continues to solidify its position in the market, but some analysts have expressed cautious optimism about Merck's tulisokibart amid competitive markets.
The pharmaceutical giant is expected to benefit from a growing pipeline and steady future dividends. Keytruda has been Merck's top-selling medicine and biggest growth driver, making it an essential asset for the company's success in cancer treatment.
* AI generated summary of articles
MRK News
15-Oct-2024 4:00 AM CST - Yahoo Finance Exelixis, MRK Collaborate for Combination Studies on HNSCC and RCC EXEL is set to evaluate investigational zanzalintinib in combination with Merck;s Keytruda (pembrolizumab) and Welireg in head and neck cancer and renal cell carcinoma, respectively.
11-Oct-2024 8:00 AM CST - Zacks Merck & Co., Inc. (MRK) Is a Trending Stock: Facts to Know Before Betting on It Merck (MRK) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over the past month,
8-Oct-2024 6:35 AM CST - Seeking Alpha Merck posts late-stage trial win for Keytruda in head and neck cancer Merck (NYSE:MRK) announced Tuesday that its Phase 3 KEYNOTE-689, designed to evaluate its anti-PD-1 therapy Keytruda as a perioperative regimen in certain patients with head and neck cancer, reached the primary goal. Citing the results of the first interim ...
6-Oct-2024 9:15 PM CST - Business Insider Barclays Remains a Buy on Merck & Company (MRK) In a report released on October 4, Carter Gould from Barclays maintained a Buy rating on Merck & Company (MRK - Research Report),
